Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: A combined analysis of ABCSG- 8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1685-1691

  Gnant, Michael ^a   Sestak, I ^b   Filipits, M ^a   Dowsett, M ^c   Balic, M ^d   Lopez Knowles, E ^c   Greil, R ^e   Dubsky, P ^a   Stoeger, H ^d   Rudas, M ^a   Jakesz, R ^a   Ferree, S ^f   Cowens, J W ^f   Nielsen, T ^g   Schaper, C ^h   Fesl, C ⁱ   Cuzick, J ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f NANOSTRING TECHNOLOGIES   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Independent Statistical Consultant New York   (United States)

ⁱ Austrian Breast and Colorectal Cancer Study Group   (Austria)

Author keywords

Early stage breast cancer (EBC); Intrinsic subtype (IS); Multigenomic testing; Node positive patients; Prognostic subtypes; Risk of recurrence (ROR)

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RNA; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; NITRILE; PROGESTERONE RECEPTOR; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER TEST; DISTANT METASTASIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PAM50 TEST; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; RNA ANALYSIS; SCORING SYSTEM; BREAST NEOPLASMS; CLASSIFICATION; LYMPH NODE; METABOLISM; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; TAMOXIFEN; TRIAZOLES;

EID: 84941729132     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv215     Document Type: Article

References (17)

1. Gnant M, Steger GG. Fighting overtreatment in adjuvant breast cancer therapy. Lancet 2009; 374(9707): 2029-2030.
2. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817-2826.
3. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28(11): 1829-1834.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687-1717.
5. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12(3): 236-244.
6. Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel) 2013; 8(2): 102-109.
7. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11(1): 55-65.
8. Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 2009; 16(4): 204-215.
9. Filipits M, Rudas M, Jakesz R et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17(18): 6012-6020.
10. Dubsky P, Filipits M, Jakesz R et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013; 24(3): 640-647.
11. Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27(8): 1160-1167.
12. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101(21): 1446-1452.
13. Gnant M, Filipits M, Greil R et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25(2): 339-345.
14. Dubsky PC, Jakesz R, Mlineritsch B et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2012; 30(7): 722-728.
15. Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31(22): 2783-2790.
16. Kelly CM, Warner E, Tsoi DT, Verma S, Pritchard KI. Review of the clinical studies using the 21-gene assay. Oncologist 2010; 15(5): 447-456.
17. Tausch C, Taucher S, Dubsky P et al. Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol 2012; 19(6): 1808-1817.